Comparing treatment lengths for venetoclax in older adults with newly diagnosed acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years or older.
- You must have been newly diagnosed with AML and have not yet started treatment for it.
- You need to be considered unfit for intensive chemotherapy by your doctor.
- You must not have certain genetic changes in your leukemia (like FLT3 or TP53 mutations).
- You must not have a specific subtype of AML called acute promyelocytic leukemia (APL).
- You must be able to swallow pills and have adequate liver and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a shorter course of venetoclax, based on early bone marrow results, works as well as the standard longer course. It is for older adults or younger patients with health issues that make standard intensive chemo too risky.
This trial tests whether a reduced-intensity stem cell transplant or venetoclax-based pills work better for patients aged 60-75 with high-risk acute myeloid leukemia who are already in remission.
This trial looks back at how older adults with acute myeloid leukemia (AML) did when treated with either standard chemotherapy or a newer combination of venetoclax and decitabine, before a stem cell transplant. The goal is to see which treatment may lead to better outcomes.
This trial tests a combination of two drugs (venetoclax and a hypomethylating agent) plus a targeted FLT3 inhibitor for older or frail patients with a specific genetic change in their acute myeloid leukemia. The goal is to see if this treatment is safe and effective without using the strongest chemotherapy.
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.